Spyre Therapeutics Inc (NASDAQ:SYRE) price on Friday, July 25, rose 1.08% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $17.79.
A look at the stock’s price movement, the close in the last trading session was $17.6, moving within a range at $17.06 and $17.95. The beta value (5-Year monthly) was 2.692. Turning to its 52-week performance, $40.26 and $10.91 were the 52-week high and 52-week low respectively. Overall, SYRE moved 13.17% over the past month.
Spyre Therapeutics Inc’s market cap currently stands at around $1.07 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-08.
Turning to the stock’s technical picture we see that short term indicators suggest on average that SYRE is a 50% Buy. On the other hand, the stock is on average a Hold as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 3 recommend SYRE as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
SYRE’s current price about 10.09% and 11.35% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 61.19, while 7-day volatility ratio is 5.69% and 6.92% in the 30-day chart. Further, Spyre Therapeutics Inc (SYRE) has a beta value of 2.83. Analysts have given the company’s stock an average 52-week price target of $45, forecast between a low of $40 and high of $71. Looking at the price targets, the low is -124.85% off current price level while to achieve the yearly target high, price needs to move -299.1%. Nonetheless, investors will most likely welcome a -152.95% jump to $45 which is the analysts’ median price.
If we refocus on Spyre Therapeutics Inc (NASDAQ:SYRE), historical trading data shows that trading volumes averaged 0.53 over the past 10 days and 545.97K over the past 3 months. The company’s latest data on shares outstanding shows there are 60.28 million shares.
The 14.97% of Spyre Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 99.30% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 13.6 million on 2025-07-15, giving us a short ratio of 19.49. The data shows that as of 2025-07-15 short interest in Spyre Therapeutics Inc (SYRE) stood at 2894.0 of shares outstanding, with shares short rising to 12.59 million registered in 2025-06-13. Current price change has pushed the stock -44.11% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SYRE stock continues to rise going into the next quarter.
